» Articles » PMID: 31024559

DHAV-1 Inhibits Type I Interferon Signaling to Assist Viral Adaption by Increasing the Expression of SOCS3

Overview
Journal Front Immunol
Date 2019 Apr 27
PMID 31024559
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Duck hepatitis A virus type 1 (DHAV-1) is one of the most lethal pathogens in the duck industry. The attenuated vaccine (the CH60 strain) is cultivated through serial passage in chicken embryos and is widely used for the prevention and control of the disease. However, the specific mechanism underlying its adaptation in chicken embryos has not been fully elucidated. In this study, we first infected chicken embryo fibroblasts (CEFs) with the DHAV-1 CH60 strain. The peak of viral proliferation occurred within 36-48 h post-infection. The different DHAV-1 strains significantly induced the expression of IFNα, IFNγ, and Suppressor of cytokine signaling 3 (SOCS3) in CEFs, and we found that SOCS3 overexpression significantly promoted viral replication. Furthermore, SOCS3 overexpression significantly inhibited the expression of IFNα but promoted the expression of IFNγ. In addition, SOCS3 overexpression clearly decreased the mRNA levels of STAT1 and STAT3 in the Janus kinase (JAK)-STAT signaling pathway and inhibited the expression of the antiviral proteins MX1 and OASL. Immune-precipitation assays indicated that SOCS3 and IFNα do not physically interact. Subcellular localization of SOCS3 and IFNα revealed that SOCS3 was mainly located in the nucleus and cytoplasm, while IFNα was located only in the cytoplasm. Co-localization of these two proteins was not observed in the cytoplasm. In conclusion, the DHAV-1 CH60 strain may inhibit the expression of IFNα by increasing the SOCS3 protein and SOCS3 can in turn decrease STAT1 and STAT3 mRNA levels, thereby inhibiting the antiviral protein MX1 and ultimately promoting viral proliferation, indirectly assisting in viral adaptation in chicken embryos.

Citing Articles

RNA-seq and microRNA association analysis to explore the pathogenic mechanism of DHAV-1 infection with DEHs.

Wang W, Li K, Zhang T, Dong H, Liu J Funct Integr Genomics. 2023; 23(2):99.

PMID: 36959488 PMC: 10035973. DOI: 10.1007/s10142-023-01022-2.


Duck hepatitis A virus type 1 mediates cell cycle arrest in the S phase.

Liu Y, Li Y, Wang M, Cheng A, Ou X, Mao S Virol J. 2022; 19(1):111.

PMID: 35761382 PMC: 9235186. DOI: 10.1186/s12985-022-01839-6.


Long Noncoding RNA Expression Rofiles Elucidate the Potential Roles of lncRNA- XR_003496198 in Duck Hepatitis A Virus Type 1 Infection.

Sui N, Zhang R, Jiang Y, Yu H, Xu G, Wang J Front Cell Infect Microbiol. 2022; 12:858537.

PMID: 35531338 PMC: 9074814. DOI: 10.3389/fcimb.2022.858537.


Promotes ALV-J Virus Replication Inhibiting JAK2/STAT3 Phosphorylation During Infection.

Mo G, Fu H, Hu B, Zhang Q, Xian M, Zhang Z Front Cell Infect Microbiol. 2021; 11:748795.

PMID: 34568100 PMC: 8461107. DOI: 10.3389/fcimb.2021.748795.


Duck Hepatitis A Virus Type 1 Induces eIF2α Phosphorylation-Dependent Cellular Translation Shutoff PERK/GCN2.

Liu Y, Cheng A, Wang M, Mao S, Ou X, Yang Q Front Microbiol. 2021; 12:624540.

PMID: 33912143 PMC: 8072014. DOI: 10.3389/fmicb.2021.624540.


References
1.
Bullen D, Darwiche R, Metcalf D, Handman E, Alexander W . Neutralization of interferon-gamma in neonatal SOCS1-/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease. Immunology. 2001; 104(1):92-8. PMC: 1783280. DOI: 10.1046/j.1365-2567.2001.01294.x. View

2.
Alexander W . Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002; 2(6):410-6. DOI: 10.1038/nri818. View

3.
Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M . SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002; 17(5):583-91. DOI: 10.1016/s1074-7613(02)00446-6. View

4.
Bode J, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F . IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003; 17(3):488-90. DOI: 10.1096/fj.02-0664fje. View

5.
Mbow M, Sarisky R . What is disrupting IFN-alpha's antiviral activity?. Trends Biotechnol. 2004; 22(8):395-9. DOI: 10.1016/j.tibtech.2004.06.002. View